LRMR

About LRMR

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell penetrating peptide (CPP) technology platform. The Company’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. It also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.